(Q38184382)

30 August 2017

Prognostic prostate tissue biomarkers of potential clinical use. (English)

1 reference

Theodorus H Van der Kwast

30 August 2017

0 references

object named as

Theodorus H Van der Kwast

series ordinal

1

0 references

publication date

1 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

464

1 reference

30 August 2017

3

1 reference

30 August 2017

293-300

1 reference

https://scigraph.springernature.com/pub.10.1007/s00428-014-1540-7

30 August 2017

0 references

cites work

Overdiagnosis in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

The role of genetic markers in the management of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Defining the threshold for significant versus insignificant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Clonal progression of prostate cancers from Gleason grade 3 to grade 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

mRNA transcript quantification in archival samples using multiplexed, color-coded probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Diagnostic and prognostic molecular biomarkers for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Combinatorial organization of the transcriptional regulatory machinery in biological control and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Molecular classification of prostate cancer using curated expression signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Genetic markers associated with early cancer-specific mortality following prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Defining and predicting indolent and low risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-014-1540-7

A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness

21 January 2018

1 reference

12 December 2020

New views into the prostate cancer genome

1 reference

12 December 2020

Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

1 reference

12 December 2020

Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer

1 reference

12 December 2020

Active surveillance: patient selection

1 reference

12 December 2020

Refined mapping of allele loss at chromosome 10q23-26 in prostate cancer

1 reference

12 December 2020

Quantitative and qualitative aspects of flow DNA measurements related to the cytologic grade in prostatic carcinoma

1 reference

12 December 2020

ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer

1 reference

12 December 2020

Large scale genomic instability as an additive prognostic marker in early prostate cancer.

1 reference

12 December 2020

10.1007/S00428-014-1540-7

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24487790